Articles On Kazia Therapeutics (ASX:KZA)

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin SYDNEY, Dec. 2, 2025 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA), an on...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin SYDNEY, Nov. 19, 2025 /PRNewswire/ — Kazia Therapeutics Limited (Nasdaq: KZIA), an o...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin SYDNEY, Oct. 27, 2025 /PRNewswire/ — Kazia Therapeutics Limited ("Kazia" or the "Com...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin SYDNEY, Oct. 7, 2025 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA), an on...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin SYDNEY, Sept. 11, 2025 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA), an...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin SYDNEY, Aug. 1, 2025 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA), an on...

On Friday the 13th of December last year, Percheron Therapeutics (ASX:PER)  CEO Dr James Garner awaited the top-line results of the phase IIb Duchenne muscular dystrophy trial from his Brisbane lounge room. The company’s clinical developmen...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin SYDNEY, July 9, 2025 /PRNewswire/ — Kazia Therapeutics (NASDAQ: KZIA) is pleased to...

A ginger group of Mayne Health shareholders argues Cosette’s $600 million offer isn’t the right prescription Artrya gets to the heart of the matter after FDA approval Zelira Therapeutics goes to the ATM for $1 million   US healthcare grou...

What’s in a name? Not much, according to the CEO of the now cashed-up Percheron, Dr James Garner. Formerly known as Antisense Therapeutics, the rare disease specialist changed its name to Percheron in January. Percheron means ‘draught horse...

Argent Biopharma packs its bags for London on a one-way ticket Patrys shares slump 50% on cancellation of key drug program Painchek targets US market for its pain detection app   Health Check is renowned biotech journo Tim Boreham’s daily...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

The ASX has ended the week lower, down 0.55pc on Friday Healthcare Sector remains defiant  Small caps led by medtech names and Lake Johnston lithium hunters   The fickle Aussie sharemarket has given back on Friday all that it has made thi...

The ASX has closed higher Healthcare leads sector gains Small caps led by KTA and FG1   The Aussie sharemarket has trimmed the fat off this morning’s substantial gains – at one stage there we were easing past the 7,350 mark and off to th...

ASX200 closes +0.28% higher Healthcare leads gains, ASX All Gold rises over +3% Small caps led by takeover target Whispir   The Australian sharemarket has ended higher on the first day of what is certain to be another week of intensely tr...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the trading day by...

The S&P ASX 200 fell -3.8% in October with mid-caps falling -6.94% and small-caps down -5.45% for the month S&P ASX 200 Energy was the only sector that closed October in the black with all Australian equity factors in red Dimerix...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Momentum trading involves taking advantage of, and making profits from, upward trends in a stock. There’s a bit of risk involved in momentum trading because in essence, you’re making a decision to buy a stock based on recent buying activiti...

The Week That Was The world looks very different this week after the addition of what Barclays economic team calls ‘a complex cocktail of geopolitical risk, mixed macro data, a nervous oil market,’ and a US Fed finding nice things to say ab...

ASX futures were down 0.82 per cent heading into 8.30 am AEDT. The market is set for a day in the red after US inflation came in hotter than expected overnight at 3.7 per cent, rising 0.3 per cent. That was the core read, which excludes...

ASX 200 closes higher for a fifth straight day All 11 Sectors make it home for supper Small caps led by Zuleika and Creasy   It’s fair to say the little battler of an Aussie sharemarket’s put in a real decent day’s work. As various part...

Kazia to de-list from ASX and maintain its NASDAQ listing IMEXHS wins $2m contract with Colombia’s National Police Force Pacific Edge says its test volumes fell in Q2   Kazia to de-list from ASX Oncology-focused drug development company K...

Stockhead’s Top 10 at shortly-before-11-ish, produced as on-time as humanly possible, despite being handicapped by some decidedly non-human and highly-unfriendly technology. On a slightly-related note, if anyone out there needs parts for an...

Benchmark index finishes Friday ahead +0.4% Sectors led by Financials Small caps dominated by Dimerix   The ASX200 is up +0.4% at  the end of Friday trade, making the week a 1% loss, which we’ll take at this stage. US equities ticked l...

PIQ came out of trading suspension and surged 13pc PIQ says the US has set a national reimbursement price for PromarkerD Kazia awarded a late breaking oral presentation for paxalisib   Proteomics International Laboratories (ASX:PIQ) surge...

Futures indicate the ASX will open positively this morning, buoyed by tech gains in the US and the encouraging news of a drop in oil prices. Here are some ASX-listed companies with news out today: Kazia Therapeutics (KZA) will present...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

According to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO defines cancer as a generic term for a large group of diseases that can affect any part of the body with malignant tumours and neoplasms. W...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

The ASX 200 had a positive finish to the day on the whole, on the back of the rates pause from the RBA Sectors were a green scene, with IT and Staples leading the way Standout small caps: Viridis, Imricor and Baby Bunting, among several ot...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Kazia Therapeutics (ASX:KZA) has announced that its lead program, paxalisib, has been awarded Fast Track Designation by the US FDA.

Avita Medical receives US FDA premarket approval for its RECELL System to treat vitiligo Telix will buy UK medical device firm Lightpoint Medical and its radio-guided surgery business SENSEI Antisense in strong position with new CEO, forme...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Kazia Therapeutics (ASX:KZA) recently attended and participated in the Cancer Moonshot Brain Cancers Forum on Glioblastoma and Diffuse Intrinsic Pontine Glioma at the White House in Washington DC.

Orphan diseases are those impacting less than 200,000 patients Orphan drug designation ensures an exclusivity period for pharma companies The average orphan drug in the US retails for US$7,000 per month   Rare or ‘Orphan’ diseases affect...

Little Green Pharma gets extended contract from the French government US FDA’s decision paves the way for a clinical involving Immuron’s drug Antisense Therapeutics announces new CEO   Cannabis stock Little Green Pharma (ASX:LGP) has been...

The ASX 200 opened half a per cent higher this morning, with 9 of 11 sectors positive in intraday trade. Among them was the consumer staples sector, which was up nearly one per cent. Small-cap dairy product producer Halo Food Co (HLF)...

Kazia Therapeutics (KZA) promotes its Chief Medical Officer, John Friend, to the role of CEO following the sudden resignation of James Garner, who held the position up until now Dr Friend’s appointment is effective immediately, with plan...

The ASX is expected to open higher on a new week after gains continued across New York on Friday night in the aftermath of quarterly reporting season. Elsewhere, eyes are fixated on central banks across the world this week, with the RBA...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The ASX slid to close flat today, after realising we were in danger of making some money Materials and Energy enjoyed a boost from Chinese manufacturing data Retail theft rates have soared as the cost of living crisis hits hard around the...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

The S&P ASX 200 rose 7.64%, in its best start to a year ever as global markets rally In a strong start to 2023 the S&P/ASX Emerging Companies index (XEC) rose ~8% in January Graphite explorer Lincoln Minerals soars more than 500% s...